玻璃体腔康柏西普注射联合微脉冲激光治疗脉络膜骨瘤继发非脉络膜新生血管性视网膜下积液的应用  

Intravitreal Conbercept injection combined with subthreshold diode micropulse laser photocoagulation for neovascularization secondary to choroidalosteoma

作　　者：孙光丽[1] 赵玥[1] 杨婷婷 姚进[1] SUN Guangli;ZHAO Yue;YANG Tingting;YAO Jin(Department of Ocular Fundus Diseases,Affiliated Eye Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]南京医科大学附属眼科医院眼底病科,江苏南京210029

出　　处：《中国肿瘤外科杂志》2022年第6期582-586,共5页Chinese Journal of Surgical Oncology

摘　　要：目的观察分析玻璃体腔注射康柏西普联合577 nm微脉冲激光(SML)治疗脉络膜骨瘤伴非脉络膜新生血管性视网膜下积液(SRF)的临床效果。方法对南京医科大学附属眼科医院2017年至2021年间就诊的8例脉络膜骨瘤患者行临床及影像学评估,治疗方案采用眼内康柏西普注射后行黄斑区微脉冲激光光凝。比较治疗前及治疗后12个月最佳矫正视力(best corrected visual acuity,BCVA)、中心视网膜厚度(central retinal thickness,CMT)的变化情况。结果3眼接受3次康柏西普注射,3眼接受2次康柏西普注射,2眼接受1次抗VEGF注射;4眼接受4次SML治疗,2眼接受3次、1眼接受2次以及1眼接受1次SML治疗。至末次随访时,7眼SRF完全吸收,1眼伴后极部囊样视网膜变性(PCRD)者残存SRF。治疗前BCVA(LogMAR)中位数为0.9(Q1~Q3,0.5~2.0),CMT中位数为393.50μm(Q1~Q3,314~460μm)。治疗后12mo BCVA中位数为0.4(Q1~Q3,0.2~1.0),CMT为208.00μm(Q1~Q3,189~231μm)。治疗前后BCVA及CMT之间差异均有统计学意义(P<0.05)。结论康柏西普眼内注射联合微脉冲激光可促进脉络膜骨瘤患者视网膜下积液的吸收,可提高患者视力,改善视功能。Objective The aim of this study is to investigate the clinical effect of intravitreal Conbercept injection combined with subthreshold diode micropulse laser photocoagulation(SML)on choroidalosteoma(CO)patients with subretinal fluid(SRF)and without CNV.Methods The clinical and image data of 8 patients with choroidal neovascularization secondary to choroidalosteoma who underwent intravitreal Conbercept injections were analyzed retrospectively.Then SML was available for eyes with SRF after anti-VEGF injection.Best corrected visual acuity(BCVA)and central macular thickness(CMT)were recorded and analyzed pre-treatment and 12 months after the treatment.Results During the follow-up period,3 eyes received thrice of Conbercept injection,3 eyes received twice,and 2 eyes received once injection respectively.Four eyes received four times,two received thrice,one received twice,and one received once of SML treatment.At the last follow-up,SRF was completely absorbed in 7 eyes,and SRF and posterior cystoid retinal degeneration(PCRD)remained in 1 eye.The median of BCVA(LogMAR)was 0.9(Q1-Q3,0.5-2.0)and CMT was 393.50(Q1-Q3,314-460)μm before treatment.After 12 months of treatment,the median of BCVA was 0.4(Q1-Q3,0.2-1.0),and CMT was 208.00(Q1-Q3,189-231)μm.There were significant differences on BCVA and CMT before and after the treatment(P<0.05).Conclusions Intraocular injection of Conbercept combined with SML promotes the absorption of SRF,which improves visual acuity and visual function in patients with choroidalosteoma.

关 键 词：康柏西普 阈值下微脉冲激光 黄斑水肿 脉络膜骨瘤 

分 类 号：R739.7[医药卫生—肿瘤]